Funding is requested to continue studies on the mechanisms that support platelet function in hemostasis and thrombosis. Platelet response to vascular injury is initiated and directed by interactions with the extracellular matrix, and sub-endothelial matrix, and sub-endothelial structures play a key role in these processes particularly during chronic arterial disease.
In specific aim 1 we will identify the sub-endothelial molecules that mediate platelet adhesion and activation, and define how their differential expression affects thrombus formation. Increasingly experimental evidence indicates that endothelial cells lining the vessels of organs have distinctly specific features, not only morphologic but also functional. The hypothesis tested in aim 2, supported by initiated experimental results, is that extracellular matrix composition is one of the structural and functional features distinguishing endothelial cells of different origin. Thus, we will isolate mouse endothelial cells from various tissues and test matrix thrombogenicity by measuring induction of platelet adhesion and aggregation in flowing blood using confocal videomicroscopy in real time. Observed phenotypic variations will lead to the identification of differences in the genetic characteristics of endothelial cells from different tissues as well as in the structural properties of the corresponding extracellular matrices that may help explain the pathogenesis of thrombotic vascular disease. Genetically induced deficiency of thrombospondin-2 (TSP2) in mice results in prolongation of the bleeding time. To explain this unexpected phenotype, in specific aim 3 we propose to evaluate selectively the thrombogenic properties of TSP2 deficient sub-endothelial matrix and the capacity of TSP2 deficient platelets to adhere to and aggregate onto appropriate substrates exposed to flowing blood. These studies will help define the role of TSP2 in vascular biology. Initial interactions tethering platelets to thrombogenic surfaces are coupled to rapid activation that is strictly required for the progression to irreversible adhesion and aggregation.
In specific aim 4 we propose to investigate the signaling mechanisms that may be elicited by different substrates and may contributed directly to the process of thrombus formation in the flowing blood. Moreover, we will use genetically manipulated mouse platelets to define the consequences of targeted Tyr->Phe mutations in the cytoplasmic domain of the beta3 subunit of integrin alphaIIbbeta3 that appear to interfere with signaling processes. These studies will contribute to clarify the integration between interaction with specific extracellular matrix components and platelet activation in relation to varying hemodynamic conditions.
In specific aim 5 we will use three-dimensional measurements in real time to study the effects of fibrinogen, fibronectin and vitronectin on the development and stability of vWF-initiated thrombi on different substrates exposed to blood flowing at normal and pathological arterial shear rates. The results obtained with the proposed studies will advance our understanding of the mechanisms of thrombus formation using well defined quantitative analysis in flowing blood, thus providing new information necessary to explain in vivo biological functions and pathological disease processes.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Program Projects (P01)
Project #
5P01HL031950-19
Application #
6713652
Study Section
Project Start
2003-01-01
Project End
2004-12-31
Budget Start
2003-01-01
Budget End
2003-12-31
Support Year
19
Fiscal Year
2003
Total Cost
$321,374
Indirect Cost
Name
Scripps Research Institute
Department
Type
DUNS #
781613492
City
La Jolla
State
CA
Country
United States
Zip Code
92037
Klann, Jane E; Kim, Stephanie H; Remedios, Kelly A et al. (2018) Integrin Activation Controls Regulatory T Cell-Mediated Peripheral Tolerance. J Immunol 200:4012-4023
Griffin, John H; Zlokovic, Berislav V; Mosnier, Laurent O (2018) Activated protein C, protease activated receptor 1, and neuroprotection. Blood 132:159-169
Sinha, Ranjeet K; Wang, Yaoming; Zhao, Zhen et al. (2018) PAR1 biased signaling is required for activated protein C in vivo benefits in sepsis and stroke. Blood 131:1163-1171
Xu, Xiaohong Ruby; Wang, Yiming; Adili, Reheman et al. (2018) Apolipoprotein A-IV binds ?IIb?3 integrin and inhibits thrombosis. Nat Commun 9:3608
Gupta, Naveen; Liu, Roland; Shin, Stephanie et al. (2018) SCH79797 improves outcomes in experimental bacterial pneumonia by boosting neutrophil killing and direct antibiotic activity. J Antimicrob Chemother 73:1586-1594
Gupta, Naveen; Sinha, Ranjeet; Krasnodembskaya, Anna et al. (2018) The TLR4-PAR1 Axis Regulates Bone Marrow Mesenchymal Stromal Cell Survival and Therapeutic Capacity in Experimental Bacterial Pneumonia. Stem Cells 36:796-806
Amar, Arun Paul; Sagare, Abhay P; Zhao, Zhen et al. (2018) Can adjunctive therapies augment the efficacy of endovascular thrombolysis? A potential role for activated protein C. Neuropharmacology 134:293-301
Kamikubo, Yuichi; Mendolicchio, G Loredana; Zampolli, Antonella et al. (2017) Selective factor VIII activation by the tissue factor-factor VIIa-factor Xa complex. Blood 130:1661-1670
Rothmeier, Andrea S; Marchese, Patrizia; Langer, Florian et al. (2017) Tissue Factor Prothrombotic Activity Is Regulated by Integrin-arf6 Trafficking. Arterioscler Thromb Vasc Biol 37:1323-1331
Subramaniam, Saravanan; Jurk, Kerstin; Hobohm, Lukas et al. (2017) Distinct contributions of complement factors to platelet activation and fibrin formation in venous thrombus development. Blood 129:2291-2302

Showing the most recent 10 out of 428 publications